Endometrial Cancer Metastatic

1 clinical trials · Condition

Record	Firm	Date
A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers. (NCT07593820)	Vall d'Hebron Institute of Oncology	2026-04-29

Every clearance here is in the API, with alerts when new ones post.